Financial Performance - The company's revenue for Q1 2024 reached ¥57,206,084.70, representing a 28.59% increase compared to ¥44,485,769.60 in the same period last year[5] - Net profit attributable to shareholders was ¥14,944,754.94, a significant increase of 91.19% from ¥7,816,548.85 year-on-year[5] - The net profit excluding non-recurring gains and losses was ¥12,072,555.57, up 87.05% from ¥6,454,127.50 in the previous year[5] - Basic and diluted earnings per share both increased to ¥0.23, reflecting a growth of 91.67% compared to ¥0.12 in the same period last year[5] - The operating profit for the first quarter of 2024 was CNY 18,725,790.88, which is a significant increase from CNY 8,937,084.49 in the previous year[30] - The total operating revenue for the first quarter of 2024 was CNY 57,206,084.70, an increase of 28.6% compared to CNY 44,485,769.60 in the same period last year[28] - The total operating costs for the first quarter of 2024 were CNY 43,035,696.85, up 15.8% from CNY 37,145,242.79 in the previous year[28] - The net profit for the first quarter of 2024 reached CNY 14,944,754.94, representing an increase of 91.5% from CNY 7,816,548.85 in the same period last year[30] - The research and development expenses for the first quarter of 2024 were CNY 5,277,861.55, slightly down from CNY 5,661,139.07 in the previous year[28] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥778,037,172.67, a decrease of 1.13% from ¥786,969,032.68 at the end of the previous year[5] - The total current assets decreased slightly to CNY 265,898,793.41 from CNY 269,712,417.33, a decline of about 1.4%[25] - The company's inventory rose to CNY 30,344,255.45 from CNY 26,198,103.20, representing an increase of approximately 15.0%[25] - Non-current assets totaled CNY 512,138,379.26, down from CNY 517,256,615.35, indicating a decrease of about 1.0%[25] - The total liabilities as of the end of the reporting period were CNY 133,480,070.13, a decrease from CNY 151,110,819.27 in the previous year[28] - The total equity attributable to the parent company was CNY 644,557,102.54, an increase from CNY 635,858,213.41 in the previous year[28] Cash Flow - The net cash flow from operating activities was ¥15,888,191.38, down 18.25% from ¥19,434,599.35 in the same period last year[5] - Cash inflow from operating activities totaled $73,627,500.46, an increase from $66,508,610.90 in the previous period, representing an increase of approximately 3.34%[34] - Cash outflow from operating activities was $57,739,309.08, compared to $47,074,011.55 previously, indicating an increase of about 22.5%[34] - Net cash flow from operating activities decreased to $15,888,191.38 from $19,434,599.35, a decline of approximately 18.5%[34] - Cash inflow from investing activities was $116,272,060.74, down from $139,453,152.16, a decrease of about 16.6%[34] - Cash outflow from investing activities decreased to $99,454,056.35 from $164,086,920.91, a reduction of approximately 39.4%[34] - Net cash flow from investing activities improved to $16,818,004.39 from a negative $24,633,768.75, indicating a significant turnaround[34] - Cash flow from financing activities resulted in a net outflow of $9,983,352.37, compared to a larger outflow of $26,516,942.65 previously, showing a decrease of about 62.4%[36] - The net increase in cash and cash equivalents was $22,709,731.27, contrasting with a decrease of $31,925,042.71 in the prior period[36] - The ending balance of cash and cash equivalents rose to $49,380,615.16 from $12,837,726.43, reflecting a substantial increase[36] Shareholder Information - Major shareholders include Yuan Yuyu with 16.63% and Xu Tao with 16.53% of shares[14] - The top 10 shareholders hold a total of 50.61% of the company's shares, indicating significant ownership concentration[14] - Yuan Yuyu has pledged 4,910,000 shares, which is approximately 44.7% of his holdings[14] - As of March 31, 2024, the company reported that Yuan Meifu and his associates hold a total of 4,508,796 shares, representing 4.40% of the total shares[16] - Tang Ying and Ye Tao together hold 5.37% of the company after a transfer of 1,320,000 shares[16] - The company has a total of 10,987,847 shares held by Yuan Yuyu, with 10,922,547 shares subject to limited sale conditions[14] - The top 10 unrestricted shareholders include Shenzhen Kaiying Technology Co., Ltd. with 4,246,049 shares, representing 6.43%[14] - The report indicates that the company is actively managing its shareholder relationships and agreements to ensure compliance and transparency[16] - The company has not reported any additional related party relationships beyond those disclosed in the shareholder agreements[16] Other Information - The company implemented a second category of restricted stock for equity incentives starting in 2023, which positively impacted net profit growth[5] - The company reported a net profit of ¥1,769.73 million after excluding share-based payment expenses, marking a year-on-year increase of 126.41%[5] - The first quarter report was not audited, indicating that the financial figures are subject to further verification[37] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the provided data[28]
迈普医学(301033) - 2024 Q1 - 季度财报